Health and Fitness Health and Fitness
Thu, May 12, 2011
Wed, May 11, 2011
Tue, May 10, 2011
Mon, May 9, 2011
Sun, May 8, 2011
Sat, May 7, 2011
Fri, May 6, 2011
Thu, May 5, 2011
Wed, May 4, 2011
Tue, May 3, 2011
Mon, May 2, 2011
Fri, April 29, 2011
Thu, April 28, 2011
Wed, April 27, 2011
Tue, April 26, 2011
Mon, April 25, 2011
Fri, April 22, 2011
Thu, April 21, 2011
Wed, April 20, 2011
Tue, April 19, 2011
Mon, April 18, 2011
Sun, April 17, 2011
Fri, April 15, 2011
Thu, April 14, 2011

Inhibitex to Host Conference Call to Report First Quarter Financial Results on May 6, 2011


//health-fitness.news-articles.net/content/2011/ .. rst-quarter-financial-results-on-may-6-2011.html
Published in Health and Fitness on Wednesday, April 27th 2011 at 8:51 GMT by Market Wire   Print publication without navigation


ATLANTA--([ BUSINESS WIRE ])--Inhibitex, Inc. (NASDAQ: INHX) announced today that it will host a conference call on Friday, May 6, 2011 at 9:00 a.m. EDT to review the Companya™s first quarter financial results and provide an update on recent corporate developments. The Company will issue a press release regarding its financial results on the same day, prior to the conference call.

Webcast Information

To access the conference call, please dial (877) 407-9210 (domestic) or (201) 689-8049 (international). A replay of the call will be available from 11:00 a.m. Eastern Time on May 6th until June 6, 2011 at midnight. To access the replay, please dial (877) 660-6853 (domestic) or (201) 612-7415 (international) and reference the account # 286 and the conference id # 371739. A live audio webcast of the call and the archived webcast will be available in the News and Events section of the Inhibitex website at [ http://www.inhibitex.com ].

About Inhibitex

Inhibitex, Inc., headquartered in Alpharetta, Georgia, is a biopharmaceutical company focused on developing products to prevent and treat serious infectious diseases. The Companya™s pipeline includes FV-100, which is in Phase 2 clinical development for the treatment of shingles, and INX-189, a nucleotide polymerase inhibitor in Phase 1b clinical development for the treatment of chronic hepatitis C infections. The Company also has additional HCV nucleotide polymerase inhibitors in preclinical development and has licensed the use of its proprietary MSCRAMM® protein platform to Pfizer for the development of staphylococcal vaccines.

For additional information about the Company, please visit [ www.inhibitex.com ].


Publication Contributing Sources